Topical and Oral Roflumilast in Dermatology: A Narrative Review.
Roflumilast tópico y oral en dermatología. Una revisión narrativa.
Apremilast
Dermatology
Dermatología
Fosfodiesterasa
Off-label
Phosphodiesterase
Psoriasis
Roflumilast
Journal
Actas dermo-sifiliograficas
ISSN: 1578-2190
Titre abrégé: Actas Dermosifiliogr
Pays: Spain
ID NLM: 0373062
Informations de publication
Date de publication:
12 Sep 2023
12 Sep 2023
Historique:
received:
22
06
2023
revised:
30
08
2023
accepted:
04
09
2023
pubmed:
15
9
2023
medline:
15
9
2023
entrez:
14
9
2023
Statut:
aheadofprint
Résumé
Oral roflumilast is a phosphodiesterase-4 inhibitor approved for the prevention of exacerbations of chronic obstructive pulmonary disease and chronic bronchitis. In dermatology, topical roflumilast is authorized by the US Food and Drug Administration for the treatment of plaque psoriasis and mild to moderate seborrheic dermatitis. Several studies have described the off-label use of roflumilast in dermatology, including a randomized controlled trial showing its usefulness in the treatment of psoriasis; case reports and small series have also reported successful outcomes in hidradenitis suppurativa, recurrent oral aphthosis, nummular eczema, lichen planus, and Behçet disease. Roflumilast has a favorable safety profile, similar to that of apremilast, and it is considerably cheaper than new generation drugs and even some conventional immunosuppressants. We review the pharmacokinetics and pharmacodynamics of topical and oral roflumilast and discuss potential adverse effects and both approved and off-label uses in dermatology. Roflumilast is a promising agent to consider.
Identifiants
pubmed: 37709133
pii: S0001-7310(23)00732-9
doi: 10.1016/j.ad.2023.09.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
spa
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.